NEW YORK, Aug. 14, 2019 /PRNewswire/ -- Inc. magazine today revealed that Competitive Health, Inc. is No. 3072 on its annual Inc. 5000 list, the most prestigious ranking of the nation's fastest-growing private companies. The list represents a unique look at the most successful companies within the American economy's most dynamic segment—its independent

SAN DIEGO, Aug. 14, 2019 /PRNewswire/ -- Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, announced today that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for its patent application directed to compositions of matter and methods of use of certain 'non-hydroxamate' inh

MANHATTAN BEACH, Calif., Aug. 14, 2019 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading patient advocacy organization, announced today that i

HOUSTON, Aug. 14, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that the Company has treated the first patients

INDIANAPOLIS, Aug. 14, 2019 /PRNewswire/ -- Athletico Physical Therapy has opened its 6th location in Indianapolis on Wednesday, August 14th and the 30th location in central Indiana. It is conveniently located in the Willow Lake West strip mall near

DALLAS, Aug. 14, 2019 /PRNewswire/ -- New research from Parks Associates finds 15% of US broadband households have a

PARKLAND, Fla., Aug. 14, 2019 /PRNewswire/ -- Parkland Cares has awarded $239,000 to six mental health-counseling centers and now the nonprofit, which focuse

VANCOUVER and HOUSTON, Aug. 14, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended

• Second Quarter Adjusted Total Revenue - $19.1 million •• Second Quarter Adjusted EBITDA - $5.7 million •• Second Quarter Gross Profit - $9.6 million •

GERMANTOWN, Md., Aug. 14, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, reported its financial results for the second quarter ended June 30, 2019.RECENT HIGHLIGHTS & ACCOM